CDKN2A/B HD have a direct oncogenic effect through loss of cell cycle inhibition and other parallel processes and are a molecular marker that influences grading and survival in IDH-mutant astrocytomas. The gene discussed is IDH2; the disease is astrocytoma (excluding glioblastoma).